One of the frustrations faced by men in the UK has been the Guideline that restrictes the use of chemotherapy (docetaxel) to only men who have already failed hormone therapy (ADT). This Guideline directly contradicts the current, cutting edge evidence that, in certain circumstances, earlier chemotherapy increases survival. The good news is that the NHS [...]
Once again we see what seems to be logical isn’t necessarily the way it actually works! In a surprising study result, it was shown that the use of intermittent androgen-deprivation therapy (IADT) for prostate cancer is not associated with fewer long-term adverse events than continuous ADT! Who would have guessed? We all thought that intermittent [...]
Survivorship has become a very important part of cancer care as more and more of us survive a longer time. If our cancer has gone into remission we still need additional care, both physical and mental care. An unanswered question in today’s healthcare delivery system is who should be providing the care, a primary care [...]
It is generally accepted that a complete biochemical response (BR) of a man’s PSA immediately after surgery is an indicator of optimal cancer control. Does this also hold true for men with lymph node invasion (LNI)? Researchers performed a single institution study of 319 men with prostate cancer and LNI who were treated with surgery [...]
ASCO GU has given us a number of interesting posters, some of which I have already written about in prior posts. Another of these posters (abstract 232) was about an analysis by Ruessel and colleagues describing cardiovascular events among men with prostate cancer using German claims data. The researchers, in a retrospective study, attempted to [...]